Summary
Gilead Sciences, Inc. (GILD) announced on January 6, 2001, a significant licensing agreement with Cubist Pharmaceuticals, Inc. This agreement grants Gilead exclusive rights to commercialize Cubist's investigational antibacterial drug, Cidecin™ (daptomycin for injection), and an oral formulation of daptomycin in 16 European countries. The commercialization is contingent upon receiving regulatory approval in those territories.
Key Highlights
- 1Gilead Sciences entered into a licensing agreement with Cubist Pharmaceuticals on January 6, 2001.
- 2The agreement provides Gilead with exclusive rights to commercialize Cidecin™ (daptomycin for injection) and an oral daptomycin formulation.
- 3The licensing covers 16 European countries.
- 4Commercialization is dependent on obtaining regulatory approval in the specified European countries.
- 5The filing includes a press release dated January 7, 2001, as an exhibit detailing this agreement.
- 6This strategic move expands Gilead's European presence and pipeline in the antibacterial sector.
Frequently Asked Questions
The primary purpose of this 8-K filing is to announce a material event: Gilead Sciences, Inc. entering into a licensing agreement with Cubist Pharmaceuticals, Inc. for the commercialization of an investigational antibacterial drug in Europe.
Gilead is licensing Cidecin™ (daptomycin for injection) and an oral formulation of daptomycin. The agreement covers 16 European countries, with commercialization rights contingent on regulatory approval.
This agreement allows Gilead to expand its portfolio with a new antibacterial drug candidate and establish a stronger commercial presence in the European market, pending regulatory approvals. It represents a strategic step in building their infectious disease franchise.
The agreement was entered into on January 6, 2001, and was reported by Gilead in this 8-K filing on January 11, 2001.